menu
    • menu
    [{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Advent Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Disease causing protein","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amphista Therapeutics \/ Advent Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Advent Life Sciences"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amphista Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Amphista Therapeutics \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amphista Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Amphista Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Amphista Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Bristol Myers Squibb"}]

    Find Clinical Drug Pipeline Developments & Deals by Amphista Therapeutics

    Menu

    Amphista Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amphista Shows New Data for Efficacy and CNS Activity of Targeted Protein Degraders

                            Details : Amphista Therapeutics is developing an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader. It is being evaluated in preclinical studies for neurodegenerative diseases.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 24, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,280.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amphista Therapeutics Achieves First Discovery Milestone in Collaboration with Bristol Myers Squibb

                            Details : Under the collaboration, Amphista is responsible for the discovery and development of small molecule protein degraders using Eclipsys™, its next-generation TPD platform and BMS is granted a global exclusive license to the resulting degraders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $30.0 million

                            April 05, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,280.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Merck Group

                            Deal Size : $1,044.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Prot...

                            Details : Amphista and Merck will collaborate to leverage Amphista's proprietary Eclipsys™ TPD platform and generate small molecule protein degraders for an initial three targets in oncology and immunology indications.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 05, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Merck Group

                            Deal Size : $1,044.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,280.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development o...

                            Details : Under the terms of the agreement, companies will work collaboratively to discover and develop small molecule protein degraders. Bristol Myers Squibb will be granted a global license to the degraders developed and will be responsible for development and c...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : $30.0 million

                            April 05, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $1,280.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Advent Life Sciences

                            Deal Size : $7.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer

                            Details : This international financing provides Amphista with a firm foundation to underpin a Series B round to progress its oncology pipeline to the clinic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 04, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Advent Life Sciences

                            Deal Size : $7.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed

                            Amphista Therapeutics

                            United Kingdom arrow
                            EPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amphista Therapeutics Appoints Leading Protein Degradation Pioneer, Ian Churcher as CSO

                            Details : Amphista believes that Ian Churcher's scientific leadership will be a tremendous addition to the Amphista team as it progresses its TPD pipeline to the clinic.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 21, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth